Biogen Idec, Inc. is an American biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen Inc. and San Diego, California-based IDEC Pharmaceuticals . Biogen, one of the oldest biotechnology companies, was founded in 1978 in Geneva by several biologists, including Phillip Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard and Charles Weissmann of Zurich University . Biogen Idec stock is a component of several stock indices such as... the S&P 500, S&P 1500, and NASDAQ-100. Biogen Idec's products include multiple sclerosis treatments Avonex and Tysabri ; the latter is also approved for treatment of Crohn's disease, and is co-marketed with Élan. Biogen Idec also makes Rituxan , a treatment for non-Hodgkin's lymphoma which is also approved for rheumatoid arthritis; Rituxan is co-marketed with Genentech.
more
| NASDAQ symbol: | BIIB |
| Founded: | 2003 |
| Headquarters: | Cambridge, Massachusetts |
| Annual revenue: | $4,097,510,000 |
| Net income: | $783,170,000 |
| Operating income: | $874,800,000 |
| Market cap: | $17,000,000,000 |
| Industries: | Biotechnology, Biological Product (except Diagnostic) Manufacturing |